bile duct cancer Sep 30, 2022 FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Sep 20, 2022 Verismo Therapeutics to Begin Phase I Trial of Autologous Cell Therapy SynKIR-110 Sep 13, 2022 Relay Therapeutics' Selective FGFR2 Inhibitor Yields 'Remarkable' Responses in Bile Duct Cancer Premium Aug 19, 2022 Verismo Therapeutics Files IND to Study Cell Therapy in Advanced Mesothelin-Expressing Solid Tumors Jun 16, 2022 Janssen Hoping to Bring Tissue-Agnostic Data on Balversa to Regulators Next Year Premium May 12, 2022 ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential Premium May 4, 2022 Juniper Biologics to Sell Helsinn's Truseltiq in Certain Asia-Pacific, Africa, Middle East Markets May 2, 2022 Alaunos Therapeutics Begins Study of Autologous Cell Therapy Using Non-Viral Gene Transfer Apr 29, 2022 Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors Apr 18, 2022 Kinnate Doses First Patient in Phase I Trial of FGFR Inhibitor Apr 6, 2022 Innovent Biologics' Pemazyre Approved by China's NMPA for Bile Duct Cancer Jan 19, 2022 FDA Clears Kinnate Biopharma's IND for FGFR Inhibitor in Bile Duct, Urothelial Cancers Jan 4, 2022 Relay Therapeutics Advances Trials of PI3Kα, FGFR2 Inhibitors Dec 20, 2021 Helsinn Group Licenses Truseltiq to Xediton Pharmaceuticals for Sale in Canada Nov 17, 2021 WUSTL Program Aims to Improve Sequencing Rates, Clinical Trial Participation Among Black Cancer Patients Premium Oct 25, 2021 TCR2 Therapeutics, BMS to Study Gavo-Cel, Opdivo, Yervoy Combos in Mesothelin-Expressing Cancers Jul 22, 2021 NICE Recommends Incyte's Pemazyre for FGFR2-Positive Bile Duct Cancer Jul 9, 2021 Chinese Regulators Accept Innovent's New Drug Application for Pemazyre May 28, 2021 FDA Approves Bile Duct Cancer Drug from Helsinn, BridgeBio Pharma With Foundation Medicine CDx May 25, 2021 Innovent Biologics Begins Phase III Trial of First-Line Pemazyre for Bile Duct Cancer in China Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
